|Bid||0.52 x 1000|
|Ask||2.40 x 2200|
|Day's Range||0.52 - 0.55|
|52 Week Range||0.34 - 0.60|
|PE Ratio (TTM)||0.06|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
On August 2, Regeneron Pharmaceuticals (REGN) posted earnings results for its fiscal second quarter of 2018, which ended on June 30. It posted strong results and raised its fiscal 2018 guidance. It registered strong sales and earnings while achieving significant product pipeline milestones.
Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.
Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.
Today, Sanofi (SNY) reported its Q2 2018 results before the market opened. The sales in the quarter were up ~0.1% at CER (constant exchange rate) and down ~2.5% at a CER/CS (constant structure), adjusting for the Bioverativ acquisition. SNY stock is trending higher today after the earnings release.
Sanofi (SNY) is one of the global pharmaceuticals majors in the world and is headquartered in Paris. It’s expected to announce its Q2 2018 earnings results on July 31. According to Wall Street analysts’ estimates, Sanofi could register adjusted diluted EPS of 1.22 euros in Q2 2018, representing a decline of ~10% YoY (year-over-year).
Sanofi (SNY) is expected to release its Q2 2018 earnings on July 31. Analysts expect SNY to report sales of 8.4 billion euros in Q2 2018, representing a YoY (year-over-year) growth of ~3.6%. Sanofi had sales of 7.9 billion euros in Q1 2018, which represented a YoY decline of ~8.7%.
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.
Click plans to seek FDA approval for its "digital therapeutics" as a type of medical device, allowing them to be prescribed by physicians and reimbursed by insurers.
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The segment contributed 67.4% of Novartis’s total revenues in the second quarter and reported a 10% growth YoY (year-over-year) at $8.9 billion.